Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
A-Z
> Overexpression cell line Target & Transduction Research
Crossing-linking Drug Evaluation
Immune Checkpoint
Drug Evaluation
ADC Targeting & CAR-T
Cell Therapy[1]
Neuroscience[2]
Diabetes & Obesity & NASH
Drug Evaluation[3]
Autoimmunity Drug Evaluation[4]
Target & Transduction Research
Cross-linking Drug Evaluation
Immune Checkpoint Drug Evaluation
ADC Targeting & CAR-T Cell Therapy
Neuroscience
Diabetes & Obesity & NASH Drug Evaluation
Autoimmunity Drug Evaluation
| Molecule | Cat. No. | Product description |
|---|
| Molecule | Cat. No. | Product description |
|---|
| Molecule | Cat. No. | Product description |
|---|
| Molecule | Cat. No. | Product description |
|---|
| Molecule | Cat. No. | Product description |
|---|
| Molecule | Cat. No. | Product description |
|---|
| Molecule | Cat. No. | Product description |
|---|
Expression analysis of human CD64 on CHO/Human CD64 Stable Cell Line by FACS. Cell surface staining using PE-labeled anti-human CD64 antibody was performed on CHO/Human CD64 Stable Cell Line with different expression levels: CHO/Human CD64 Stable Cell Line (Low Expression) (Cat. No. SCCHO-ATP062L); CHO/Human CD64 Stable Cell Line (Medium Expression) (Cat. No. SCCHO-ATP062M); CHO/Human CD64 Stable Cell Line (High Expression) (Cat. No. SCCHO-ATP062H).
Bioactivity analysis of anti-human 4-1BB antibody through CHO/Human CD32b Stable Cell Line (Medium Expression) (Cat. No. SCCHO-ATP060M) crosslinking to test whether in a CD32b-dependent manner to strengthen the agonistic activity. The EC50 of anti-human 4-1BB antibody is approximately 0.18 μg/mL through CHO/Human CD32b Stable Cell Line (Medium Expression) crosslinking.
Blocking activity of anti-human PD-1 antibody (FOLD). This Raji/Human PD-L1 Stable Cell Line (Cat. No. SCRAJ-STT075) was incubated with serial dilutions of antibodies in the presence of reporter cells expressing human PD-1. The max induction fold was approximately 22.47.
[1]. Yu B, Jiang T, Liu D. BCMA-targeted immunotherapy for multiple myeloma. J Hematol Oncol. 2020;13(1):125. Published 2020 Sep 17. doi:10.1186/s13045-020-00962-7
[2]. Raimondo L, Oliveira ĹAF, Heij J, et al. Advances in resting state fMRI acquisitions for functional connectomics. Neuroimage. 2021;243:118503. doi:10.1016/j.neuroimage.2021.118503
[3]. Boland ML, Laker RC, Mather K, et al. Resolution of NASH and hepatic fibrosis by the GLP-1R/GcgR dual-agonist Cotadutide via modulating mitochondrial function and lipogenesis. Nat Metab. 2020;2(5):413-431. doi:10.1038/s42255-020-0209-6
[4]. Xue C, Yao Q, Gu X, et al. Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer. Signal Transduct Target Ther. 2023;8(1):204. Published 2023 May 19. doi:10.1038/s41392-023-01468-7
This web search service is supported by Google Inc.
